



Combined targeting of STAT3, STAT5, and heme-oxygenase-1 overcomes resistance in BCR-ABL1⁺ cells

CDDO-Me inhibits proliferation and viability in TKI-sensitive and TKI-resistant BCR-ABL1⁺ cell lines and primary leukemic cells



CDDO-Me synergizes with BCR-ABL1-targeting TKI



The Hemeoxygenase-1 inhibitor SMA-ZnPP sensitizes CML cells against CDDO-Me and TKI

